reinaldo-franquimachin@uiowa.edu
Mentor: Fenghuang Zhan, M.D./Ph.D.
Lab Room: 3257 MERF
Lab Phone: 319-384-1339

Elucidating the molecular mechanisms that lead to drug resistance in multiple myeloma

Zhan X, Yu W, Franqui-Machin R, Bates ML, Nadiminti K, Cao H, Amendt BA, Jethava Y, Frech I, Zhan F, Tricot G. Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma. Oncotarget. 2017 Nov 27;8(67):111213-111224. doi: 10.18632/oncotarget.22740. eCollection 2017 Dec 19. PubMed PMID: 29340048; PubMed Central PMCID: PMC5762316.

Hao M, Franqui-Machin R, Xu H, Shaughnessy J Jr, Barlogie B, Roodman D, Quelle DE, Janz S, Tomasson MH, Sanderson RD, Qiu L, Frech I, Tricot G, Zhan F. NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma. Leukemia. 2017 Jul;31(7):1648-1650. doi: 10.1038/leu.2017.115. Epub 2017 Apr 12. PubMed PMID: 28400617; PubMed Central PMCID: PMC5508075.

Franqui-Machin R, Wendlandt EB, Janz S, Zhan F, Tricot G. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? Oncotarget. 2015 Dec 1;6(38):40496-506. doi: 10.18632/oncotarget.5800. Review. PubMed PMID: 26415231; PubMed Central PMCID: PMC4747348.

Xia J, Franqui Machin R, Gu Z, Zhan F. Role of NEK2A in human cancer and its therapeutic potentials. Biomed Res Int. 2015;2015:862461. doi:10.1155/2015/862461. Epub 2015 Feb 1. Review. PubMed PMID: 25705694; PubMed Central PMCID: PMC4330945.